摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[2-[2-[2-(4-Diethylcarbamoylphenyl)ethyl]phenoxy]ethyl]-4-(1,3-dihydro-2H-benzimidazol-2-on-1-yl)piperidine | 356071-39-1

中文名称
——
中文别名
——
英文名称
1-[2-[2-[2-(4-Diethylcarbamoylphenyl)ethyl]phenoxy]ethyl]-4-(1,3-dihydro-2H-benzimidazol-2-on-1-yl)piperidine
英文别名
N,N-diethyl-4-[2-[2-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethoxy]phenyl]ethyl]benzamide
1-[2-[2-[2-(4-Diethylcarbamoylphenyl)ethyl]phenoxy]ethyl]-4-(1,3-dihydro-2H-benzimidazol-2-on-1-yl)piperidine化学式
CAS
356071-39-1
化学式
C33H40N4O3
mdl
——
分子量
540.706
InChiKey
GENAHCDIOLDSOI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.4
  • 重原子数:
    40
  • 可旋转键数:
    11
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    65.1
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • Phenoxyalkylamine derivatives useful as opioid receptor agonists
    申请人:——
    公开号:US20030171370A1
    公开(公告)日:2003-09-11
    A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: 1 wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), 2 “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH 2 and the like, “n” represents 0 to 2, R 1 represents a hydrogen atom, a halogen atom and the like, R 2 , R 3 , and R 7 to R 14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R 4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R 5 represents a hydrogen atom, a halogen atom and the like, R 6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R 5 and R 6 , R 7 and R 8 , R 9 and R 10 , or R 11 and R 12 may bind to each other to form a cyclic structure.
    一种用于预防和/或治疗神经系统疾病的药物,其活性成分为以下通用式(I)或其药理学可接受的盐所代表的化合物: 其中,X代表以下通用式(II)、(III)、(IV)、(V)或(VI)所代表的基团,“A”代表饱和或不饱和的3-至6-成员碳环基团等,“B”代表CH2等,“n”代表0至2,R1代表氢原子、卤素原子等,R2、R3和R7至R14代表氢原子、可能被取代的较低烷基基团等,R4代表氢原子、可能被取代的较低烷基基团等,R5代表氢原子、卤素原子等,R6代表饱和或不饱和的单环或双环碳环基团等,且R5和R6、R7和R8、R9和R10,或R11和R12可以结合在一起形成环状结构。
  • Phenoxyalkylamine derivatives useful as opioid delta receptor ligands
    申请人:Tsushima Masaki
    公开号:US20050148583A1
    公开(公告)日:2005-07-07
    A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH 2 and the like, “n” represents 0 to 2, R 1 represents a hydrogen atom, a halogen atom and the like, R 2 , R 3 , and R 7 to R 14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R 4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R 5 represents a hydrogen atom, a halogen atom and the like, R 6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R 5 and R 6 , R 7 and R 8 , R 9 and R 10 , or R 11 and R 12 may bind to each other to form a cyclic structure.
    一种用于神经系统疾病的预防和/或治疗的药物,其包括以下通式(I)所表示的化合物或其药学上可接受的盐作为活性成分: 其中,X代表以下通式(II),(III),(IV),(V)或(VI)所表示的基团,“A”代表饱和或不饱和的3-至6-成员的碳环基团等,“B”代表CH2等,“n”代表0至2,“R1”代表氢原子,卤原子等,“R2”,“R3”和“R7”至“R14”代表氢原子,可被取代的较低烷基基团等,“R4”代表氢原子,可被取代的较低烷基基团等,“R5”代表氢原子,卤原子等,“R6”代表饱和或不饱和的单环或双环碳环基团等,“R5”和“R6”,“R7”和“R8”,“R9”和“R10”,或“R11”和“R12”可以结合在一起形成环状结构。
  • PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS
    申请人:Meiji Seika Kaisha, Ltd.
    公开号:EP1256575B1
    公开(公告)日:2005-08-17
  • US6916822B2
    申请人:——
    公开号:US6916822B2
    公开(公告)日:2005-07-12
查看更多

同类化合物

(E,Z)-他莫昔芬N-β-D-葡糖醛酸 (E/Z)-他莫昔芬-d5 (4S,5R)-4,5-二苯基-1,2,3-恶噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S,5R,5''R)-2,2''-(1-甲基亚乙基)双[4,5-二氢-4,5-二苯基恶唑] (4R,5S)-4,5-二苯基-1,2,3-恶噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4R,4''R,5S,5''S)-2,2''-(1-甲基亚乙基)双[4,5-二氢-4,5-二苯基恶唑] (1R,2R)-2-(二苯基膦基)-1,2-二苯基乙胺 鼓槌石斛素 黄子囊素 高黄绿酸 顺式白藜芦醇三甲醚 顺式白藜芦醇 顺式己烯雌酚 顺式-白藜芦醇3-O-beta-D-葡糖苷酸 顺式-桑皮苷A 顺式-曲札芪苷 顺式-二苯乙烯 顺式-beta-羟基他莫昔芬 顺式-a-羟基他莫昔芬 顺式-3,4',5-三甲氧基-3'-羟基二苯乙烯 顺式-1-(3-甲基-2-萘基)-2-(2-萘基)乙烯 顺式-1,2-双(三甲基硅氧基)-1,2-双(4-溴苯基)环丙烷 顺式-1,2-二苯基环丁烷 顺-均二苯乙烯硼酸二乙醇胺酯 顺-4-硝基二苯乙烯 顺-1-异丙基-2,3-二苯基氮丙啶 非洲李(PRUNUSAFRICANA)树皮提取物 阿非昔芬 阿里可拉唑 阿那曲唑二聚体 阿托伐他汀环氧四氢呋喃 阿托伐他汀环氧乙烷杂质 阿托伐他汀环(氟苯基)钠盐杂质 阿托伐他汀环(氟苯基)烯丙基酯 阿托伐他汀杂质D 阿托伐他汀杂质94 阿托伐他汀杂质7 阿托伐他汀杂质5 阿托伐他汀内酰胺钠盐杂质 阿托伐他汀中间体M4 阿奈库碘铵 锌(II)(苯甲醛)(四苯基卟啉) 银松素 铜酸盐(5-),[m-[2-[2-[1-[4-[2-[4-[[4-[[4-[2-[4-[4-[2-[2-(羧基-kO)苯基]二氮烯基-kN1]-4,5-二氢-3-甲基-5-(羰基-kO)-1H-吡唑-1-基]-2-硫代苯基]乙烯基]-3-硫代苯基]氨基]-6-(苯基氨基)-1,3,5-三嗪-2-基]氨基]-2-硫代苯基]乙烯基]-3-硫代 铒(III) 离子载体 I 铀,二(二苯基甲酮)四碘- 钾钠2,2'-[(E)-1,2-乙烯二基]二[5-({4-苯胺基-6-[(2-羟基乙基)氨基]-1,3,5-三嗪-2-基}氨基)苯磺酸酯](1:1:1) 钠{4-[氧代(苯基)乙酰基]苯基}甲烷磺酸酯 钠;[2-甲氧基-5-[2-(3,4,5-三甲氧基苯基)乙基]苯基]硫酸盐 钠4-氨基二苯乙烯-2-磺酸酯